{,AB)S!4?X~K-'-!?F,FF'|#?N^<+,
SYSTEM PROCESSING...
{,AB)S!4?X~K-'-!?F,FF'|#?N^<+,
SYSTEM PROCESSING...
Posted: 2025-05-01 16:03:35 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-05-01 16:03:58 UTC
Verified By
Rollup News
AMIX, a biotech company targeting fibrotic diseases, is poised for growth due to strategic partnerships, upcoming catalysts, a strong IP portfolio, and a tiny float, making it highly volatile with massive upside potential.
Fibrotic disease target with unmet need
Strategic partnerships ($50M+)
Upcoming catalysts
Strong IP portfolio
Tiny float & high volatility
High volatility